Real-Life Experience With First-Line Therapy Bortezomib Plus Melphalan and Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma Ineligible for High Dose Chemotherapy With Autologous Stem-Cell Transplantation

Real-Life Experience With First-Line Therapy Bortezomib Plus Melphalan and Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma Ineligible for High Dose Chemotherapy With Autologous Stem-Cell Transplantation

Introduction: Currently, the regimen with bortezomib plus melphalan and prednisone (VMP) is a standard treatment for multiple myeloma and it is recommended as the first-line therapy for patients with multiple myeloma (MM) ineligible for high-dose chemotherapy with autologous stem-cell transplantatio...

Full description

Bibliographic Details
Main Authors: Gabriele Buda, Maria Livia Del Giudice, Elisabetta Antonioli, Francesco Ghio, Enrico Orciuolo, Riccardo Morganti, Francesca Martini, Michela Staderini, Sara Galimberti, Mario Petrini
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Medicine
Subjects:
myeloma
chemotherapy
chemotherapy resistance
bortezomib
melphalan
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2021.712070/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2021.712070/full

Similar Items